BMRA
Biomerica, Inc.
BMRA has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over BMRA overall, supported by stronger fundamentals and stronger modeled upside.
BMRA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
BMRA's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BMRA PE Valuation
BMRA has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BMRA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect BMRA's losses to grow, with revenue declining.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
BMRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.67 | -$0.15 |
| Q2 2026 | -$1.30 | +$0.86 |
| Q1 2026 | -$1.45 | +$0.87 |
| Q4 2025 | -$1.49 | +$1.23 |
| Q3 2025 | -$1.52 | +$1.44 |
| Q2 2025 | -$2.16 | +$0.72 |
| Q1 2025 | -$2.32 | +$0.64 |
| Q4 2024 | -$2.72 | +$0.32 |
BMRA is still losing money, but far less than before: $1.67 per share over the past year, against $4.96 at its worst in mid-2021.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BMRA on earnings quality, reporting a profit while its opponent remains loss making.
BMRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.3M | -8.3% |
| Q2 2026 | $875K | +17% |
| Q1 2026 | $987K | -12% |
| Q4 2025 | $1.2M | -26% |
| Q3 2025 | $1.4M | -24% |
| Q2 2025 | $749K | -33% |
| Q1 2025 | $1.1M | +10% |
| Q4 2024 | $1.6M | +4.4% |
BMRA's revenue has slid since its 2022 peak: $1M last quarter, down 8.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -97% | -16 points |
| Q2 2026 | -175% | +34 points |
| Q1 2026 | -132% | -23 points |
| Q4 2025 | -113% | -53 points |
| Q3 2025 | -81% | -5.3 points |
| Q2 2025 | -209% | -72 points |
| Q1 2025 | -108% | +89 points |
| Q4 2024 | -61% | +42 points |
BMRA's operating margin was −97% last quarter, down 16 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BMRA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over BMRA on profitability, with a higher operating margin.
BMRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$802K | -$534K |
| Q2 2026 | -$912K | -$251K |
| Q2 2025 | -$661K | +$407K |
| Q2 2024 | -$1.1M | -$105.2K |
| Q1 2024 | -$1.8M | -$70.4K |
| Q4 2023 | -$848K | +$389.7K |
| Q3 2023 | -$1.7M | -$88.1K |
| Q2 2023 | -$962.8K | +$3.3M |
BMRA has burned cash in almost every quarter: −$4M over the past year, against −$4M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BMRA on cash generation, producing positive trailing cash flow while its opponent burns cash.
BMRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.5% | +286K shares |
| 1 year | +43% | +999K shares |
| 3 years | +86% | +1.5M shares |
| 5 years | +121% | +1.8M shares |
| Available history | +169% | +2.1M shares |
BMRA has 3M diluted shares, up 43% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over BMRA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BMRA Net Leverage
BMRA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
BMRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.0 | Neutral |
| Stochastic | 10.9 | Oversold |
BMRA's weekly RSI is 34 (neutral) and its Stochastic is 11 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BMRA PE vs Healthcare Sector
BMRA has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BMRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.81 | 28% below |
| 20 week MA | $1.83 | 29% below |
| 50 week MA | $2.08 | 38% below |
| 100 week MA | $2.83 | 54% below |
| 200 week MA | $5.62 | 77% below |
BMRA is in a downtrend: it's below all five of its weekly moving averages, and 77% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BMRA on trend strength, trading above more of its moving averages.
BMRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.6 | $39.8 | +84% |
| 2021 | $39.8 | $33.6 | -15% |
| 2022 | $33.6 | $29.7 | -12% |
| 2023 | $29.7 | $10.0 | -66% |
| 2024 | $10.0 | $2.52 | -75% |
| 2025 | $2.52 | $2.70 | +7.1% |
| 2026 YTD | $2.70 | $1.30 | -52% |
BMRA has finished lower in four of the last six years. It's down 52% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BMRA on returns for 2026, with the stronger performance.